bullet1 Babies Sacrificed for Drug Testing Experiments.

The story below reveals babies are likely being sacrificed as testing grounds for the drug companies. This is contrary to equal protection and equal security to all as stated by Canada's Constitution and Charter of Rights and Freedoms, and as to Universal Human Declarations signed by Canada, back in December 1998, and to current times.  This reckless disregard of an infant's well being is regardless of an adult's duty to another by no discrimination as to:  age, race, color, sex, or mental or physical disadvantage, or by marital status of the family.  (The weak or the poor should not be picked on by the strong and/or the rich or by private enterprise involved in research).   Concerns of Donna Young


Drug licensing policies make children 'sentinel canaries,' experts argue

Mon Nov 10, 5:16 PM ET  


HELEN BRANSWELL


TORONTO (CP) - For too long children have been "sentinel canaries" when it comes to prescription drugs, with regulating authorities requiring little or no verification that drugs are safe for children before they are used, a group of experts is arguing. In a commentary published Tuesday in the Canadian Medical Association Journal, they say it's time for the evidence-based medicine rules that are used to ensure prescription drugs are safe for adults to be applied to the pediatric population.


"We live in a world of rules. And I think parents would not unnaturally assume that the rules that apply to drug approvals for them are the same as . . . for their kids. And they would be wrong," Dr. Michael Rieder, a pediatric clinical pharmacologist, said in an interview Monday.


It is often argued that it is unethical to test pharmaceuticals in children, both because they cannot give informed consent and because there may be more risk of harm from drugs during the early stages of life.


Rieder and three colleagues from the Children's Hospital of Western Ontario turn that argument around, however, suggesting it may be unethical to prescribe drugs to children if there is no evidence the drugs are safe in this vulnerable population.


"If you look at the adverse drug reaction literature, kids have been the sentinel canary for a lot of bad things in drug theory for quite some time. And I would argue that's not the best segment of society who should be serving that function," he said.


Traditionally new drugs are tested first in animals, then in adult humans. Once they are licensed for use, however, doctors can and do prescribe them to children - but without the benefit of clinical data to show if they will be effective or what the appropriate dosage should be.


That is largely guess work. And it isn't always right. Rieder noted a drug called theophylline, once commonly used in the treatment of asthma, was prescribed for some time in children before it was realized that it wasn't working. It turned out that kilogram for kilogram, children required higher doses of the drug than adults.


With other drugs, however, adult doses are unsafe for children and must be cut back.


"One of the problematic issues in efficacy is that for many drugs, we have an idea what the best dose could be. But we could be wrong. Like totally wrong. And there's very little way of finding out," Rieder acknowledged.


The associate chief of research at the research institute of Toronto's Hospital for Sick Children agreed more pediatric drug trials need to be done.


But Dr. Denis Daneman suggested the field is evolving rapidly, with a growing numbers of trials being undertaken.


"I'm very comforted by the fact that people have increasingly talked about it," Daneman said.


"If you actually look at the number of clinical trials going on in pediatrics - clinical trials involving medication - it's quite substantial."


Rieder agreed, but noted this work is mainly done on new drugs companies are trying to bring to market, not existing drugs which are being prescribed for children without the support of clinical data.


In part that's because of a U.S. provision that grants drug manufacturers an extra six months of patent protection for a drug if it is tested in children.


"Six months sounds like nothing. But to a moderately expensive U.S. drug or European drug, it's hundreds of millions of dollars in patent protection," Daneman said.


This provision is helping to change the field, the commentary said. But as yet no similar provision has been adopted here. And the authors argue Canada shouldn't be content to simply ride on American coattails.


"Is it fair for us to let the U.S. haul the freight on this? As a policy I think it shows less than noteworthy leadership," Rieder said. "We're not hauling our weight as a sovereign state."


Full Story at:   http://story.news.yahoo.com/news?tmpl=story&cid=1843&ncid=737&e=11&u=/cpress/20031110/ca_pr_on_he/health_pediatric_drugs

____________________________

Other links:   http://www.cmaj.ca/cgi/content/full/169/10/1033

References  

    1. Steinbrook R. Testing medications in children. N Engl J Med 2002;347:1462-70. Free Full Text available. {HYPERLINK "/cgi/ijlink?linkType=FULL&journalCode=nejm&resid=347/18/1462"}
    2. Moore TJ, Weiss SR, Kaplan S, Blaisdell CJ. Reported adverse drug events in infants and children under 2 years of age. Pediatrics 2002;110:e53.
    3. Abi Khaled L, Ahmad F, Brogan T, Fearnley J, Graham J, MacLeod S, et al. Prescription medication use by one million Canadian children. Paediatr Child Health 2003;8(Suppl A):6A-56A.
    4. Kwan C, Steer E, Rieder MJ, Matsui D. Barriers to drug investigation in children in Canada: perspectives from academic and community practice. Paediatr Child Health 2002;7(Suppl A):44A.
    5. Cohen SN. The Pediatric Pharmacology Research Unit (PPRU) Network and its role in meeting pediatric labeling needs. Pediatrics 1999;104:644-5.{HYPERLINK "/cgi/ijlink?linkType=FULL&journalCode=pediatrics&resid=104/3/S1/644"} Free text available.
    6. Food and Drug Administration Modernization Act of 1997, Public Law 105–115, 105th Congress, 111 Stat 2296 (1997 Nov 21).
    7. Department of Health and Human Services, US Food and Drug Administration. The pediatric exclusivity provision: January 2001 status report to Congress. Rockville (MD): The Administration; 2001.
    8. Department of Health and Human Services, Food and Drug Administration. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients; final rule. Federal Register 1998;63(231):66631-72. See Medline{HYPERLINK "/cgi/external_ref?access_num=10338880&link_type=MED"}
    9. US Food and Drug Administration Center for Drug Evaluation and Research. Pediatric drug development. Available: www.fda.gov/cder/pediatric/   (accessed 2003 July 18).
    10. Best Pharmaceuticals for Children Act, Public Law 107-109, 107th Congress, 115 Stat 1408 (2002 Jan 4).
    11. Conroy S. Unlicensed and off-label drug use: issues and recommendations. Pediatr Drugs 2002;4:353-9.
    12. Medical Research Council of Canada, Natural Sciences and Engineering Research Council of Canada and Social Sciences and Humanities Research Council of Canada. Tri-Council policy statement: Ethical conduct for research involving humans. Ottawa: The Councils; 1998.

__________________________


Search this www.lotusbirth.com web site for :  AAP policy, SOGC policy, ACOG policy; Placenta; Fetus to Neonate Circulation; 30-second clamping; World Health Organization and Dupont ; Circumcision ; Dr. Sarah Buckley's Declaration ; Canadian Criminal Codes and when a baby is a person; and any other subject you may be interested in child birth.  Search Lotusbirth


(Reference from Protect Babies http://www.123-baby-birth.com)   Search at Google this web site for the " No Policies " on equal protection to babies at from the various government officials who appointed representatives to protect the public on medical policies and practices; also the "No policies" of the various medical associations, societies, and colleges did not live up to no form of discrimination to women or the child of any kind.  It is believed they had a duty to have a policy of equal protection and security of person, regardless of:  age, mental or physical disadvantages ; race, color, social or marital status of the pregnant lady ; or belief or faith of the family, or genetic type of blood sought for by medical researchers, for stem cell matching, and use of white cells, mature red cells, platelets, enzymes, hormones, and plasma.


contact:   Donna Young, Mother and Grandmother

Home:   www.lotusbirth.com

A medical web site to visit:  

  www.cordclamping.com